During “Head Start” Trials, Mortality and Morbidity Have Decreased
New “Head Start 4” uses experience, molecular studies to customize safe central nervous system tumor treatment.
Ultrasounds Find Thyroid Nodules Missed by Physical Exams in Pediatric Cancer Survivors
Should ultrasounds be standard in long-term follow-up of patients with previous radiation treatment?
Predicting the Efficacy of Immune-Based Therapies for Pediatric Solid Tumors
Expression of HLA class I and ß-2-microglobulin may show how susceptible some cancers are to T-cell based immunotherapies.
Advanced Care and Collaborative Research
Read summaries of several research and clinical developments from the past year.
Anicteric Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Children
Certain diagnostic criteria ignore anicteric VOD, leading to a delay in treatment.
Virotherapy Shows Promise Against Highly Malignant Pediatric Tumors
Using viruses to treat cancers with poor prognoses may lead to better outcomes for patients.
Issues Confronting AYA Oncology Patients
Adolescents and young adults with cancer have unique needs that may be contributing to the plateau in survival rates, despite improved survival rates in other age groups.
The Immune System May Play a Key Role in Viral Therapy’s Effectiveness Against Tumors
A new study suggests that immune system suppression may hinder viral therapy's ability to fight cancer.
The Numbers Are In: Deaths From Central Nervous System Cancers
Pediatric cancer-related deaths result in a large part from CNS cancers. A new study explores the data.
At any given time there are a large number of clinical trials taking place at Nationwide Children’s that offer state-of-the-art therapies and additional treatment options to your child.
Biospecimen Core Resource
Nationwide Children’s is processing tumor and tissue for The Cancer Genome Atlas, the nation’s largest cancer genome study. Learn more about our role as a Biospecimen Core Resource.
Pediatric Tumor Bank